anticalin


Also found in: Wikipedia.

anticalin

A protein derived from a lipocalin (also known as cytosolic fatty acid binding protein) which is genetically engineered to modify its binding properties. Anticalins have the advantage of a monoclonal antibody’s specificity for small lipid molecules (e.g., steroids, bilins, retinoids and lipids), better tissue penetration and thermostability, but without the large size (they are 8-fold smaller) and can also batched in E coli, eliminating the need for animal extraction..
References in periodicals archive ?
a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the closing of its previously announced underwritten public offering and the exercise in full of the underwriters' option to purchase additional shares.
Pieris' proprietary suite of agonistic costimulatory anticalin proteins, when fused to a tumor-targeting antibody, can activate the immune system preferentially in the tumor microenvironment.
The collaboration and license agreement will see both firms assess novel bispecific immuno-oncology agents that integrate Pieris' anticalin technology with select Seattle Genetics cancer-targeted antibodies.
By applying a mutation and selection process, it is possible to select Anticalin proteins that can specifically bind to very diverse protein targets in a monovalent fashion.
Pieris AG and The Sanofi Group have expanded their discovery and development partnership to include a novel multi-specific Anticalin program.
The adaptability of the Anticalin scaffold has already allowed Pieris to develop therapeutic and diagnostic product candidates with custom designed functionality.
a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the pricing of its previously announced underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $8.
Pieris' Anticalin technology and Antibody-Anticalin bispecific approach are intended to overcome the limitations of currently available immuno-oncology products.
a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, today announced that the first patient has been dosed in the Company's Phase I clinical trial of PRS-343, its lead proprietary immuno-oncology drug candidate.